Manuel Fabre

[Manuel Fabre @fabre_de]

$SGMO
https://t.co/MD6neakv9n

[Manuel Fabre @fabre_de]

@Franca_ole

[Manuel Fabre @fabre_de]

@MELANIATRUMP
Ma'am, please help us with so-called rare diseases. Thank you.

[Manuel Fabre @fabre_de]

@realDonaldTrump
Mr. President Trump, please help us with so-called rare diseases. Thank you.

[Manuel Fabre @fabre_de]

@realDonaldTrump Mr. President Trump, please help us with so-called rare diseases. Thank you.

[Manuel Fabre @fabre_de]

@DBATTAGLIAYtube Bitcoing subirá...mi pregunta es las demás criptomonedas que pasará con ellas?

[Manuel Fabre @fabre_de]

$SGMO
Sangamo Therapeutics Files Initial Beneficial Ownership Statement for Principal Accounting Officer Nikunj Jain

[Manuel Fabre @fabre_de]

$SGMO

[Manuel Fabre @fabre_de]

$SGMO
https://t.co/i1popTrkwt

[Manuel Fabre @fabre_de]

$SGMO
https://t.co/h9VDgSFbKY

[Manuel Fabre @fabre_de]

@InvestInAssets sangamo therapeutics .(sgmo)

[Manuel Fabre @fabre_de]

$SGMO
https://t.co/BZ62gr0bvS

[Manuel Fabre @fabre_de]

@Parsifaler sangamo therapeutics👍

[Franca_ole @Franca_ole]

Key results of the $SGMO STAAR study
Positive eGFR slope at 52 weeks: Mean +1.965 mL/min/1.73 m²/year (95% CI: –0.153 to 4.083) in all 32 treated patients – confirmed as the primary endpoint by the FDA for accelerated approval
Long-term data over 104 weeks: continues to be positive (+1.747 mL/min/1.73 m²/year; CI: –0.106 to 3.601) in 19 patients
Secondary endpoints:
Stable α-gal-A activity for up to 4.5 years;
All 18 patients who previously received enzyme replacement therapy (ERT) are independent of it;
Lipid markers (Lyso-Gb3) largely stable;
Improvements in cardiac parameters, quality of life (SF-36), pain reduction, physical function, sweating
Safety profile: Predominantly Grade 1/2 side effects (fever, headache, nasopharyngitis); no treatment discontinuations due to safety.

[Manuel Fabre @fabre_de]

$sgmo
https://t.co/mRcvtHTYWa

[Manuel Fabre @fabre_de]

@BiotechAnalysst .... the International Society on Thrombosis and Hemostasis 2025. It also lists the names of the presenters/authors.

[Manuel Fabre @fabre_de]

@BiotechAnalysst In summary, this image shows details for an upcoming international oral presentation on June 20, 2025, titled "Health-Related Quality of Life and Joint Health with Giroctocogene Fitelparvovec Gene Therapy," to be held in Washington D.C., USA, at the International Society on...

[Manuel Fabre @fabre_de]

$sgmo
https://t.co/vY9r0Cafp6

[Sangamo Therapeutics @SangamoTx]

Join our CEO, Sandy Macrae, for a fireside chat at the H.C. Wainright 6th Annual Neuro Perspectives Hybrid Conference on Tuesday, June 17th at 7:00 a.m. EDT.

For the latest information, visit our website:
https://t.co/uSkWhIgBfA

#GenomicMedicine #Neurology

[Manuel Fabre @fabre_de]

$SGMO
https://t.co/ddAxvvL3Ds

[Manuel Fabre @fabre_de]

$SGMO
https://t.co/Gj70gsqVRR

[Sangamo Therapeutics @SangamoTx]

🔬 ICYMI: Exciting progress was highlighted last week during the prestigious #PresidentialSymposium at #ASGCT2025, showcasing promising data for the potential treatment of prion disease. To view this presentation and more Sangamo content from ASGCT, https://t.co/EkI1IrwToJ